MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex

Andriy E Belevych1, Sarah E Sansom, Radmila Terentyeva

  • 1The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America.

Plos One
|December 14, 2011
PubMed

Insights

In heart failure, increased muscle-specific microRNAs (miRNAs) reduce phosphatase activity, leading to excessive ryanodine receptor (RyR2) phosphorylation and arrhythmias. This study identifies a key mechanism driving heart failure-related cardiac dysfunction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • MicroRNA Research

Background:

  • Heart failure (HF) is associated with arrhythmogenic spontaneous sarcoplasmic reticulum Ca(2+) release and afterdepolarizations.
  • Abnormally high activity of ryanodine receptors (RyR2s) and their enhanced phosphorylation are implicated in HF-related arrhythmias.
  • The precise molecular mechanisms driving RyR2 hyperphosphorylation in HF remain unclear.

Purpose of the Study:

  • To investigate the hypothesis that increased muscle-specific microRNAs (miRNAs) contribute to RyR2 phosphorylation alterations in HF by targeting RyR2-localized phosphatase activity.
  • To elucidate the role of specific miRNAs, such as miR-1 and miR-133, in regulating protein phosphatase 2A (PP2A) activity in cardiac myocytes during HF.

Main Methods:

  • Analysis of hearts from canines with chronic HF characterized by ventricular dysfunction.
  • Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to measure miR-1 and miR-133 levels.
  • Western blot analysis to assess protein phosphatase 2A (PP2A) subunit expression.
  • Luciferase reporter assays to validate miRNA targets.
  • Pharmacological inhibition of phosphatase activity and Ca(2+)/calmodulin-dependent protein kinase (CaMKII) in cardiac myocytes.

Main Results:

  • Muscle-specific miRNAs miR-1 and miR-133 were significantly increased in HF myocytes.
  • Expression of protein phosphatase 2A (PP2A) catalytic and regulatory subunits, targets of miR-1 and miR-133, was decreased in HF myocytes.
  • Decreased PP2A activity in HF myocytes correlated with enhanced CaMKII-mediated RyR2 phosphorylation (Ser-2814, Ser-2030) and increased pro-arrhythmic diastolic Ca(2+) waves and afterdepolarizations.
  • CaMKII inhibition normalized spontaneous diastolic Ca(2+) waves in HF myocytes.

Conclusions:

  • Altered levels of muscle-specific miRNAs contribute to abnormal RyR2 function in HF.
  • These miRNAs depress phosphatase activity localized to RyR2, leading to excessive RyR2 phosphorylation.
  • This mechanism promotes abnormal Ca(2+) cycling and increases the propensity for cardiac arrhythmias in heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: